Barclays keeps CHF 93.00 target for Sandoz stock

Published on 10/15/2026 at 11:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Barclays keeps a CHF 93.00 target for Sandoz on October 13, 2026. Sandoz stock costs EUR 79.66 on October 15, 2026, with a CHF 30.7 billion market value.

Target and operating milestones

Barclays kept a CHF 93.00 price target for Sandoz on October 13, 2026.
First-half 2026 sales reached USD 5.8 billion on August 5, 2026.
Sandoz stock trades at EUR 79.66 at 11:04 a.m. CEST at Lang & Schwarz on October 15, 2026.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz (CH1243598427) has a CHF 93.00 price target from Barclays, which maintained its Buy rating in a report dated October 13, 2026, according to The Globe and Mail. The stock was trading at EUR 79.66 at Lang & Schwarz on October 15, 2026 at 11:04 a.m. CEST.

Barclays holds the target

The Barclays target sits in the broader CHF 72.00 to CHF 80.00 range cited in recent analyst commentary, while the CHF 93.00 level is higher than that range. The market value of Sandoz was CHF 30.7 billion in the latest October 2026 stock analysis, according to Simply Wall St.

What does margin growth mean?

Sandoz reported first-half 2026 sales of USD 5.8 billion, up 5 percent at constant exchange rates, while biosimilars represented 33 percent of net sales. Core EBITDA margin expanded by 90 basis points to 20.9 percent, according to the Yahoo Finance transcript for the August 5, 2026 earnings call. Management confirmed full-year 2026 guidance and targeted another 100 basis points of core EBITDA margin improvement.

The chronology shows three concrete steps. On August 5, 2026, first-half sales reached USD 5.8 billion. On September 8, 2026, Sandoz outlined Bio100, a plan to build a biosimilar portfolio of more than 100 products by 2040, as reported by Drugnews. On October 13, 2026, Barclays maintained the CHF 93.00 target.

Upcoming reporting date

A third-quarter sales update was cited for October 26, 2026, by Headtopics. That date will give investors a fresh test of the biosimilar growth rate and margin trajectory.

Price and market value

Sandoz stock was trading at EUR 79.66 at Lang & Schwarz on October 15, 2026 at 11:04 a.m. CEST. Its market capitalization was CHF 30.7 billion in October 2026, keeping valuation and execution central to the analyst debate.

The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.